Journalartikel
Autorenliste: Janschek, Elisabeth; Woelfler, Monika Martina; Zeppernick, Magdalena M.; Meinhold-Heerlein, Ivo
Jahr der Veröffentlichung: 2020
Seiten: 658-665
Zeitschrift: Der Gynäkologe
Bandnummer: 53
Heftnummer: 10
ISSN: 0017-5994
eISSN: 1433-0393
DOI Link: https://doi.org/10.1007/s00129-020-04663-7
Verlag: Springer
Abstract:
Approximately 10-15% of women suffer from endometriosis, a chronic disease of pubescent females. While dysmenorrhoea is seen as the cardinal symptom of endometriosis, many patients complain of chronic pelvic pain. Progesterone resistance as well as inflammation characterizes endometriosis on a cellular level. Systemic treatment focuses on analgesia, anti-inflammation, and elevation of progesterone levels. Non-steroidal anti-rheumatic drugs (NSAR), progestins, combined oral contraceptives, intrauterine systems (IUS) loaded with progestogen, and gonadotropin releasing hormone (GnRH analoges) are used. In Germany, dienogest and danazol are licensed for endometriosis treatment. The latter is rarely prescribed due to its androgenic side effects. Elagolix, which is an orally administered GnRH antagonist, has been licensed in the US to treat endometriosis-associated pain. Additional drugs are currently under investigation in preclinical and clinical studies.
Zitierstile
Harvard-Zitierstil: Janschek, E., Woelfler, M., Zeppernick, M. and Meinhold-Heerlein, I. (2020) Drug treatment of endometriosis, Der Gynäkologe, 53(10), pp. 658-665. https://doi.org/10.1007/s00129-020-04663-7
APA-Zitierstil: Janschek, E., Woelfler, M., Zeppernick, M., & Meinhold-Heerlein, I. (2020). Drug treatment of endometriosis. Der Gynäkologe. 53(10), 658-665. https://doi.org/10.1007/s00129-020-04663-7
Schlagwörter
Dienogest; Elagolix; GUIDELINE; Non-steroidal anti-rheumatic drugs; PAIN
